Conclusion: At seven years of follow-up, regular prostate cancer screening was associated with a 22 percent greater rate of prostate cancer diagnosis, but with no reduction in prostate cancer mortality. These findings support the recommendations of the USPSTF for prostate cancer screening, especially ...
In this video, Ram Pathak, MD, an assistant professor at Mayo Clinic, discusses how the United States Preventative Services Task Force (USPSTF) grade D recommendation against PSA screening has resulted in a disproportionate increase in the incidence of metastatic prostate cancer among minorit...
I fear that in this day and age where clinicians are crunched for time and trying to make ends meet, providers will not have the time to screen for prostate cancer risk or to offer prostate screening unless the patient demands it. Thus, although the evidence may not support it, routine sc...
Evidence Review The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostate cancer and subsequent treatment of screen-detected prostate cancer. The USPSTF also commissioned a review of existing decision analysis models and the overdiagnosis rate of PSA-based screening...
This systematic review to support the 2018 US Preventive Services Task Force Recommendation Statement on screening for prostate cancer summarizes
USPSTF concluded that the evidence is limited on the benefit of screening among men older than 70 years, thus, providing a grade D recommendation against PSA-based screening for prostate cancer in men 70 years and older. The USPSTF further concluded that the evidence was insufficient to make a...
Rates of prostate biopsy and prostate cancer incidence have declined in unison, with a shift towards tumours being of higher grade and stage upon detection. Despite the recommendation, some physicians report ongoing willingness to screen appropriately selected men, and many men report intending to ...
The USPSTF concluded thatPSA screeningmay reduce risk for prostate cancer mortality but is associated with harms including false-positive results, biopsy complications and overdiagnosis in 20% to 50% percent of screen-detected prostate cancers.
The objective of this study is to examine recent changes in SDM and prostate cancer screening following recent USPSTF recommendations.A retrospective cross-sectional study among men aged 50 years or older were conducted using 2015 and 2018 National Health Interview Survey data (=10,926). Outcomes ...
Background Prostate-specific antigen (PSA) remains as the most used biomarker in the detection of early prostate cancer (PCa). Clinical practice guidelines (CPGs) are produced to facilitate incorporation of evidence into clinical practice. This is partic